Management of Atrial Fibrillation With Flecainide : the AFFLEC Study

This is a multicentre non interventional observational study with the objective to follow up patients with atrial fibrillation who based on current indications are treated with per os flecainide , for cardiac pulse maintenance.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Atrial Fibrillation Arrhythmias, Cardiac Cardiovascular Diseases Heart Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Erythros Stavros Hospital, Athens, Greece

About this study

the study objectives are

record safety and efficiency of flecainide as antiarrythmic treatment in atrial fibrillation
study of flecainide in ST interval

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

patients with history of atrial fibrillation
patients able to give informed consent

Exclusion criteria

patients with coronary disease or other cardiopathy with left heart champer affected

Treatment and study plan

Primary outcomes

ST interval and repolarization measures of myocardia in patients under treatment of flecainide

Time frame: 6months

Sponsors and collaborators

Lead sponsor

Hellenic Cardiovascular Research Society

Other

Registry information

Official study title

Multicentre Non Interventional Study in the Management of Atrial Fibrillation With Flecainide

Important dates

Study start: 2014
Primary completion: 2015
Study completion: 2015
First posted: Jul 15, 2014
Registry last updated: Sep 7, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed